Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) is a leading precision oncology medicine company headquartered in Cambridge, Massachusetts. Founded in 2014, the company focuses on the discovery and development of small molecule, tumor-agnostic therapies designed to target families of oncogenic mutations across various cancers.
The core of Black Diamond’s innovative approach lies in its proprietary Mutation-Allostery-Pharmacology (MAP) platform. This platform enables the identification and targeting of allosteric mutations in key cancer-related kinases, offering new therapeutic options for patients with limited treatments available.
The company’s lead product candidate, BDTX-189, is a potent inhibitor targeting non-canonical and oncogenic mutations of ERBB kinases, including the epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The development pipeline also includes BDTX-1535, an advanced fourth-generation EGFR inhibitor, and BDTX-4933, targeting KRAS, NRAS, and BRAF mutations in solid tumors.
Recent clinical updates highlight the potential of BDTX-1535 in treating non-small cell lung cancer (NSCLC) and glioblastoma (GBM), demonstrating efficacy against over 50 clinically relevant non-classical EGFR mutations and resistance mutations like C797S. This candidate is currently advancing through Phase 2 trials, with promising results expected in 2024.
Black Diamond Therapeutics has also established significant collaborations and partnerships to bolster its research and development efforts. These collaborations aim to enhance the understanding of mutation landscapes and accelerate the delivery of new therapies to patients.
For more information, visit Black Diamond Therapeutics.
Black Diamond Therapeutics, Inc. (BDTX) reported Q2 2022 results, highlighting a cash position of $160.9 million to fund operations into Q3 2024. The company appointed Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer, enhancing its leadership. BDTX-1535's Phase 1 study has commenced, with the first patient dosed. R&D expenses decreased to $16.2 million from $26.7 million year-over-year, while net loss narrowed to $22.9 million compared to $34.4 million in Q2 2021. Clinical updates for BDTX-1535 are expected in 2023.
Black Diamond Therapeutics, a precision oncology medicine company, announced that its CEO, David M. Epstein, will participate in the panel discussion titled Bullseye - Targeted Oncology - Quanta of Targets at the Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022, at 10:20 a.m. ET. The event can be viewed live via the company's investor relations website, and a replay will be available for 90 days. Black Diamond focuses on developing MasterKey therapies for genetically defined cancers using its proprietary MAP drug discovery engine.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will present a company update at the Jefferies Global Healthcare Conference on June 8, 2022, at 3:00 PM ET in New York. The presentation will highlight the company’s advancements in precision oncology and MasterKey therapies aimed at treating genetically defined cancers. A live webcast will be available on their investor relations website, with a replay accessible for 90 days post-event. Black Diamond focuses on innovative oncology solutions for patients with limited treatment options.
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) has appointed Dr. Sergey Yurasov as Chief Medical Officer, replacing Karsten Witt, who transitions to an advisory role. Dr. Yurasov brings over 25 years of experience in oncology drug development, with expertise in EGFR mutant non-small cell lung cancer and glioblastoma. His appointment comes as the company advances its MasterKey therapies, including lead programs BDTX-1535 and BDTX-4933. The transition is seen as pivotal for the company's strategy in addressing unmet medical needs in precision oncology.
Black Diamond Therapeutics, a precision oncology medicine company, announced that its CEO, David M. Epstein, Ph.D., will present an update on the company's progress at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand viewing starting May 24, 2022, at 7:00 a.m. ET. Interested parties can access the webcast in the investor relations section of the company’s website, where a replay will also be available for 90 days. The company focuses on developing MasterKey therapies for genetically defined cancers.
Black Diamond Therapeutics has published findings revealing 22 new oncogenic HER2 driver mutations discovered through its MAP discovery engine. The research, appearing in the AACR's Cancer Research Journal, emphasizes the importance of identifying these mutations for developing novel inhibitors aimed at treating HER2-mutant cancers. The study validated 37 HER2 driver mutations from 820 variants analyzed, demonstrating Black Diamond's capacity for drug discovery focused on precision oncology. This advancement highlights the necessity of innovative treatment options for patients with specific genetic profiles.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the dosing of the first patient in the Phase 1 study of BDTX-1535 for glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). The company reported financial results for Q1 2022, highlighting a cash position of approximately $179.7 million, down from $209.8 million in Q4 2021. R&D expenses decreased to $17.8 million, while net loss narrowed to $25.5 million from $30.3 million year-over-year. The company extends its cash runway into Q3 2024, emphasizing its strategic focus on BDTX-1535 and BDTX-4933.
Black Diamond Therapeutics (NASDAQ: BDTX) announced a strategic realignment to enhance operational efficiency and extend its cash runway into Q3 2024. The company will discontinue the development of BDTX-189 and reduce its workforce by approximately 30%. Focus will shift to advancing key programs BDTX-1535 and BDTX-4933, aimed at addressing unmet needs in precision oncology. BDTX-1535 is in Phase 1 development for glioblastoma, while BDTX-4933 is undergoing IND-enabling studies. These moves are expected to support significant upcoming clinical milestones.
Black Diamond Therapeutics (Nasdaq: BDTX) announced the dosing of the first patient in its Phase 1 clinical study of BDTX-1535, a MasterKey inhibitor targeting EGFR mutations in non-small cell lung cancer (NSCLC) and glioblastoma (GBM). The trial aims to address the unmet needs of patients with these conditions, especially those resistant to current treatments. BDTX-1535 is anticipated to benefit over 60,000 GBM patients annually in key markets, with updates expected in the second half of 2023. The company utilizes its MAP drug discovery engine to develop precision oncology therapies.
Black Diamond Therapeutics (Nasdaq: BDTX) has announced that its President and CEO, David M. Epstein, Ph.D., will give a presentation on the company’s advancements at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 14, 2022, at 10:00 a.m. ET. Interested parties can access a live webcast of the discussion through the investor relations section of Black Diamond's website. The company specializes in precision oncology and is focused on developing novel MasterKey therapies for patients with genetically defined cancers.
FAQ
What is the current stock price of Black Diamond Therapeutics (BDTX)?
What is the market cap of Black Diamond Therapeutics (BDTX)?
What does Black Diamond Therapeutics do?
Where is Black Diamond Therapeutics headquartered?
What is the Mutation-Allostery-Pharmacology (MAP) platform?
What is BDTX-189?
What are the key clinical-stage programs at Black Diamond?
What recent achievements has Black Diamond Therapeutics made?
What are upcoming milestones for Black Diamond Therapeutics?
What collaborations is Black Diamond involved in?
When was Black Diamond Therapeutics founded?